- The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's TSHA TSHA-105, AAV9-based gene therapy for SLC13A5-related epilepsy.
- Related: Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development
- SLC13A5 deficiency is a form of infantile epilepsy caused by mutations in the SLC13A5 gene.
- This type of epilepsy manifests as developmental delay and seizures beginning within the first few days of life.
- Orphan designation in the European Union includes benefits such as protocol assistance, reduced regulatory fees, and market exclusivity.
- Related content: Benzinga's Full FDA Calendar
- Price Action: TSHA shares are up 2.88% at $18.33 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsepilepsygene therapyOrphan Drug Designation
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
